Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Смертность при легочной артериальной гипертензии: прогнозирование с помощью модели стратификации риска, предложенной рекомендациями Европейского общества по легочной гипертензии 2015 года
2017-08-01
SCID: 54.1/pju92b95
Discuss with AI
1-year mortalityCOMPERA registryEuropean PH guidelinespulmonary arterial hypertensionrisk stratification
Figures from the paper
Abstract (AI)
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5-10% and >10%, respectively. This risk assessment strategy awaits validation.We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation.Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups.An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.
Key Findings
1
Mortality differed significantly across low-, intermediate-, and high-risk strata, with all pairwise comparisons showing p<0.001.
2
Observed 1-year mortality was 2.8% for low-risk patients, 9.9% for intermediate-risk patients, and 21.2% for high-risk patients.
3
The abbreviated 2015 European pulmonary hypertension guideline risk model was evaluated in 1,588 newly diagnosed PAH patients from the COMPERA registry.
4
The abbreviated guideline-based model provided accurate mortality estimates in patients with pulmonary arterial hypertension.
5
The risk assessment strategy remained valid during follow-up and across major pulmonary arterial hypertension subgroups.
Research Object
Patients with newly diagnosed pulmonary arterial hypertension (PAH) enrolled in the COMPERA European pulmonary hypertension registry
Research Subject
Validation and accuracy of the 2015 European pulmonary hypertension guidelines risk stratification model for estimating 1-year mortality across risk strata and PAH subgroups
Publication Details
Publication Date
2017-08-01
Journal
Publisher
ISSN
Cited by
692
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Cited by6
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2022
Risk stratification and medical therapy of pulmonary arterial hypertension2018
Risk stratification and treatment goals in pulmonary arterial hypertension2024
Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension2019
Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival2020
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2022